v3.26.3
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (UNAUDITED) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Revenue:        
Total revenue $ 275,358 $ 216,833 $ 755,243 $ 519,147
Costs and operating expenses:        
Selling and marketing expense 59,853 41,267 158,661 123,355
General and administrative expense (see note 9) 69,278 51,973 195,534 168,458
Research and development expense 33,838 21,624 97,511 69,739
Total costs and operating expenses 256,042 184,191 703,719 562,445
Income (Loss) from operations 19,316 32,642 51,524 (43,298)
Other expense, net:        
Interest income 6,332 7,360 19,985 9,482
Interest expense (9,249) (13,507) (31,286) (45,497)
Changes in fair value of financial instruments 0 (2,081) 0 (52,285)
Other income (expense), net 475 (89) (24,607) (18,447)
Total other expense, net (2,442) (8,317) (35,908) (106,747)
Income (Loss) before income taxes 16,874 24,325 15,616 (150,045)
Income tax expense (1,624) 0 (1,513) 0
Net income (loss) 15,250 24,325 14,103 (150,045)
Other comprehensive income (loss), net of tax:        
Unrealized loss on available-for-sale securities (153) 0 (408) 0
Foreign currency translation adjustments (481) 79 (633) 538
Comprehensive income (loss) 14,616 24,404 13,062 (149,507)
Net income (loss) 15,250 24,325 14,103 (150,045)
Deemed dividend from Series D redeemable convertible preferred stock 0 0 0 (384,436)
Adjustments of redeemable convertible preferred stock to redemption value 0 0 0 (85,433)
Net loss attributable to common shareholders basic 15,250 24,325 14,103 (619,914)
Net loss attributable to common shareholders diluted $ 15,250 $ 24,325 $ 14,103 $ (619,914)
Net income (loss) per share attributable to common shareholders:        
Basic (in dollars per share) $ 0.05 $ 0.09 $ 0.05 $ (4.83)
Diluted (in dollars per share) $ 0.05 $ 0.08 $ 0.05 $ (4.83)
Weighted-average shares used in computing net income (loss) per share attributable to common shareholders:        
Basic (in shares) 283,894,498 282,099,073 283,118,633 128,447,673
Diluted (in shares) 295,140,869 297,211,838 294,241,534 128,447,673
Molecular profiling services        
Revenue:        
Total revenue $ 262,707 $ 207,587 $ 725,760 $ 484,593
Costs and operating expenses:        
Cost of services 89,172 66,980 243,383 193,195
Pharma research and development services        
Revenue:        
Total revenue 12,651 9,246 29,483 34,554
Costs and operating expenses:        
Cost of services $ 3,901 $ 2,347 $ 8,630 $ 7,698